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Abstract: Advanced atherogenesis is characterized by the presence of markers of enhanced 
prothrombotic capacity, attenuated ﬁ brinolysis, and by clinical conditions associated with defective 
coagulation. Diabetes may be associated with enhanced lesion instability and atherosclerotic plaque 
rupture. Plaques obtained from 206 patients undergoing carotid endarterectomy were divided into 
diabetic (type 2) and nondiabetic and analyzed by Western blotting and immunohistochemistry 
to detect tissue factor (TF), metalloproteinases (MMP)-2, -8, -9, and ﬁ brin/ﬁ brinogen related 
antigens, and in situ zymography to detect MMP activity. Plasma samples were quantiﬁ ed for 
TF procoagulant activity, C-reactive protein, ﬁ brinogen and D-dimer. Diabetic and symptomatic 
patients with hypoechogenic plaques had increased plasma TF activity and D-dimer, compared 
with those with hyperechogenic plaques (p = 0.03, p = 0.007, respectively). Diabetic, symptom-
atic patients had higher plasma D-dimer levels than asymptomatic patients (p = 0.03). There 
was a signiﬁ cant correlation between intramural TF levels and D-dimer in diabetic patients with 
symptomatic disease (p = 0.001, r2 = 0.4). In diabetic patients, plasma ﬁ brinogen levels were higher 
in patients with hypoechogenic plaques (p = 0.007). Diabetic patients with ulcerated plaques had 
higher plasma D-dimer and MMP-8 levels than those with ﬁ brous plaques (p = 0.02, p = 0.01, 
respectively). This data suggests that currently available circulating markers may be clinically 
useful to select diabetic patients at higher risk of atherothrombosis. Increased procoagulant activity 
in diabetic patients may be linked to increased mural remodeling.
Keywords: Diabetes, atherosclerosis, carotid artery, tissue factor, D-dimer, matrix 
metalloproteinase.
Introduction
Diabetes mellitus is associated with severe atherosclerosis in humans (Paoletti et al 
2006). Patients with metabolic syndrome are at increased risk for both progressive carotid 
atherosclerosis and coronary heart disease (Diamant et al 2002). Chronic perturbation of 
diabetic vasculature leads to increased complexity of atherosclerotic plaques (King et al 
1998). Furthermore, diabetics have enhanced lesion instability (Death et al 2003).
Several studies have suggested an association between circulating tissue factor (TF) and 
progression of atherothrombosis. Diabetes, hypercholesterolemia, and smoking, are associated 
with a higher incidence of thrombotic complications. Poorly controlled diabetic patients 
have increased circulating TF activity associated with increased blood thrombogenicity 
(Viles-Gonzalez et al 2006). These ﬁ ndings suggest that high levels of circulating TF may 
be the mechanism of action responsible for increased thrombotic complications associated 
with the presence of diabetes (Sambola et al 2003; Steffel et al 2006; Meerarani et al 2007). 
Increased expression of TF in high-grade stenosis of the ICA is associated with plaque 
destabilization evidenced clinically both by a history of previous ischemic symptoms and the 
detection of microemboli in long-term transcraneal Doppler ultrasonography monitoring of 
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the ipsilateral middle cerebral artery (Jander et al 2001). Diabetics 
with vascular disease have raised plasma ﬁ brinogen (Lipinski 
2001; Corrado et al 2006), which is considered to be an important 
risk factor in atherosclerosis (Tkac et al 2003; Krupinski 
et al 2007). Fibrinogen remains an independent risk factor for 
both cardiac and extracardiac atherothrombotic complications. 
Fibrinogen and its effector, thrombin, substantially determine 
the extent and outcome of atherothrombotic complications, 
because they are the molecules linking the mutually dependent 
events in atherogenesis, coagulation/ﬁ brinolysis, rheology, and 
inﬂ ammation (Shah 2006; Krupinski et al 2007a, 2007b).
The mechanisms that mediate vascular complications 
in diabetic patients are not yet fully understood. Patients 
with an increased risk of symptomatic vascular disease 
and development of type 2 diabetes have an atherogenic 
‘prediabetic’ state. This can be measured by increased 
triglyceride levels, increased systolic blood pressure, and 
decreased levels of HDL cholesterol occurring before the 
onset of type 2 diabetes (Haffner 2002). Elevated glucose 
induces discordant metalloprotease (MMP) expression 
from endothelial cells and macrophages (Ho et al 2007). 
High glucose induces endothelial cell expression and 
activity of MMP-1, -2, but reduces expression of MMP-3. 
In monocytes MMP-9 activity and expression is induced by 
high glucose (Death et al 2003). Dermal ﬁ broblasts from 
diabetic patients were also found to have elevated MMP-2,-3 
production (Wall et al 2003). The increased MMP-1, -2, -9 
activities induced by high glucose exposure could promote 
matrix degradation thereby accelerating atherogenesis and 
potentially reducing plaque stability in diabetes (Derosa et al 
2007; Turu et al 2007).
This study was designed to identify links between 
the prothrombotic state, intramural remodeling, and 
inﬂ ammatory markers in diabetic patients with vulnerable 
carotid disease (Rubio et al 2005).
Materials and methods
Patients
Patients (n = 206) undergoing symptomatic and asymptomatic 
carotid endarterectomy were used in this study. Symptomatic 
patients presented with stroke or transient ischemic attack 
(TIA) in the territory of the affected carotid artery within 6 
months prior to endarterectomy according to North American 
Symptomatic Carotid Endarterectomy Trial criteria (NASCET 
1991). Patients were divided into diabetics (n = 53) and nondia-
betics (n = 73) according to clinical evidence of type II diabetes 
(Table 1). All patients had CT-scan and MR imaging, followed 
by MR angiography or conventional arteriography and the 
degree of carotid stenosis was calculated according to Bladin 
and colleagues (1995). Patients were screened for the presence 
of bilateral pathology (50% contralateral stenosis). Duplex 
colour ultrasound analysis was used to classify plaque stability 
in terms of hypoechogenic or hyperechogenic according to the 
Gray-Weale criteria (1988). The presence of vascular risk factors 
(VRF) was recorded and previous statin or antiplatelet treatment 
was noted. If a patient was anticoagulated he/she was excluded 
from further analysis. For quantitative assay of D-dimer expres-
sion and high sensitivity C-reactive protein (hsCRP) patients 
with history of acute arterial or venous thromboembolism, active 
infections or inﬂ ammatory conditions, renal failure, hepatic 
disease, neoplasms, recent trauma, or surgery were excluded. 
The study was approved by the local ethical committee.
Blood sampling and tests
Plasma samples were collected after overnight fasting and 
prior to surgery, frozen in liquid nitrogen and stored at −80 °C 
for further processing. D-dimer was measured in plasma by 
automated latex enhanced immunoassay on IL Coagulation 
Systems (IL Test D-Dimer, 20008500, Biokit, SA). HsCRP 
was tested in EDTA-plasma samples by particle enhanced 
immunonephelometry using BN Systems (Dade Behring, 
Marburg, Germany).
MMP-2, MMP-8, and MMP-9 levels were determined by 
commercially available enzyme-linked immunosorbent assay 
(ELISA, Biotrak Amersham Pharmacia, UK). Our laboratory 
reference ranges for healthy controls were: 41 ± 27.8 ng/ml 
Table 1 Characteristics of study patients
Variable Diabetics Nondiabetics
 (n = 87) (n = 119)
Age, y 68 69
Male/Female 72/20 105/19
Hypertensión 69 84
Hypercholesterolemia 66 66
Cigarette smoking 70 87
Bilateral carotid disease* 35 47
Symptomatic carotid dis 61 83
Stenosis severity 83 85
CAD 30 31
PVD 25 34
Antiplatelets 58 83
Statins 33 37
hypoechogenic plaque
 on ultrasound 36 52
Ulcerated plaque
 on histology 47 54
Notes: *more than 50% contralateral stenosis on ultrasound
Abbreviations: CAD, coronary artery disease; PVD, peripheral vascular disease.
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for MMP-9 (n = 62, 58% males, mean age 43 years, normal 
range 25–97 ng/ml), 3.10 ± 1.47 ng/ml for MMP-8 (n = 57, 
normal range 0.16–6 ng/ml) and 630.8 ± 101.8 ng/ml for 
MMP-2 (n = 40, 47% males, mean age 43 years, normal range 
427–835 ng/ml). The mean intra-assay coefﬁ cients of variation 
were <10% for all MMPs.
Circulating TF activity was measured by Actichrome TF, 
a chromogenic assay (American Diagnostica, Inc., Stamford, 
CT, USA). This method measures the peptidyl activity of 
human TF in lysed cells and human plasma. Samples were 
mixed with human factor VIIa and human factor X. The 
reagents were incubated at 37 °C, allowing for the formation 
of the TF/factor VIIa complex (TF/VIIa), and the activation 
of the human factor X to factor Xa. The amount of factor Xa 
generated was measured by its ability to cleave Septrozyme® 
Xa, a highly speciﬁ c chromogenic substrate for factor Xa, 
which was added to the reaction solution. The cleaved 
substrate released a para-nitroaniline chromophore into the 
reaction solution. The absorbance was measured at 405 nm 
and compared with values obtained from a standard curve 
generated using known amounts of active human TF.
All other standard hematological and biochemistry analysis 
were routinely performed at the hospital laboratory.
Carotid specimens
Carotid specimens were excised by the vascular surgeon 
without damage to the plaque surface. They were immediately 
rinsed in 0.9% saline and cut longitudinally into two specimens. 
One was snap frozen in liquid nitrogen and stored at −80 °C 
and the other was ﬁ xed for 24 hours in buffered formalin and 
later cryoprotected in 30% sucrose and frozen in OCT for 
histology. Plaque morphology was assessed immediately after 
surgery and later by histology of H&E stained sections. Plaques 
were classiﬁ ed according to AHA classiﬁ cation as unstable 
(ulcerated or ulcerated with hemorrhage) or stable (ﬁ brous or 
ﬁ brous with old hemorrhage) (Stary et al 1995).
Western blotting
For gel electrophoresis, samples (n = 30, 15 diabetics and 
nondiabetics) were homogenized with 300 µl of ice-cold 
homogenisation buffer containing 1% sodium deoxycholate, 
1% v/v Triton X-100, 100 µM EDTA, 1 µM leupeptin, 1 µM 
pepstatin, 1 µM aprotinin, and 200 µM PMSF. Samples were 
centrifuged at 5000 rpm for 2 min and stored in aliquots at 
–20 °C. The protein concentration of each sample was deter-
mined using the Bradford assay. SDS-PAGE (10%) was carried 
out as previously described (Slevin et al 2002). Membranes 
were incubated overnight at 4 °C with antihuman MMP-9 
and MMP-8 antibodies (Chemicon MAB13415; MAB19045, 
respectively) (Turu et al 2006) and anti-human antibody to TF 
(American Diagnostica Inc, ID4501, 1:100). The remaining 
procedure was performed according to standard protocols.
Statistical analysis
Normality of continuous variables was checked by 
Kolmogorov-Smirnov normality test. Normally distributed 
clinical, histological and Western blotting variables were 
compared between groups by analysis of variance (ANOVA). 
When samples were not normally distributed, Kruskal-Wallis 
was used. Differences in frequencies of categorical variables 
were checked by chi-square test.
Results
Table 1 summarizes clinical characteristics of the studied 
population. There was no difference in age, sex, vascular 
risks factor distribution, presence of bilateral carotid disease, 
carotid stenosis severity, plaque stability on ultrasound, coex-
isting coronary artery disease (CAD), or peripheral vascular 
disease (PVD) between diabetic and nondiabetic patients. Fur-
thermore, as summarized in Table 2, there were no differences 
in biochemical parameters studied between diabetics and 
nondiabetics. However, when diabetes was associated with 
symptomatic carotid disease or vulnerable carotid plaques, 
differences were signiﬁ cant as presented below.
Hemostatic markers in diabetic patients
Diabetic and symptomatic patients with hypoechogenic 
plaques identiﬁ ed on ultrasound had increased plasma TF 
Table 2 Biochemical parameters of study patients
Variable Diabetics Nondiabetics P
TF plasma activity 13.9 13.3 0.7
TF plaque expression 0.75 0.7 0.8
 (ng/ml)
D-dimer in plasma 793 731 0.9
 (ng/ml)
D-dimer in plaque 6.2 5.1 0.5
MMP-2 (ng/ml) 804 764 0.6
MMP-8 (ng/ml) 6.2 9.1 0.2
MMP-9 (ng/ml) 80.7 111 0.2
hsCRP (mg/l) 8.8 6.8 0.6
Fibrinogen (g/l) 4.3 4.1 0.4
WB counts 7700 7271 0.6
Cholesterol 4.8 5.2 0.1
LDL-C (mmol/l) 2.8 3.0 0.4
TG (mmol/l) 1.4 1.5 0.4
Abbreviations: hsCRP, high sensitivity C-reactive protein; LDL-C, low density 
lipoprotein-cholesterol; MMP, metalloproteinases; TF, tissue factor; TG, triglycerin; 
WB, white blood cells.
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activity compared with nondiabetics (16.34 PM vs 10.4 PM, 
p = 0.03; Figure 1a). Regression analysis in the same group 
of patients showed a strong correlation between TF activity 
in plasma and intramural levels of MMP-8 (p = 0.03, r2 = 0.2, 
Figure 1b). There was also a correlation between intramural 
TF levels and both circulating active MMP-8 and intramural 
D-dimer in symptomatic, diabetic patients with hypoecho-
genic plaque on ultrasound (p = 0.02, r2 = 0.6, Figure 2a; 
p = 0.001, r2 = 0.4, Figure 2b, respectively). 
Markers of fi brinolysis and infl ammation
Diabetics with symptomatic carotid disease had higher levels of 
plasma D-dimer if the plaque was hypoechogenic on ultrasound 
as compared with patients with hyperechogenic plaques 
(p = 0.007, Figure 3a). Diabetics with histologically identiﬁ ed 
ulcerated plaques had higher plasma D-dimer than diabetics 
with ﬁ brous plaques (p = 0.02; Figure 3b). Diabetic patients 
with symptomatic carotid disease had higher plasma D-dimer 
than nondiabetics (p = 0,03; Figure 3c). Plasma ﬁ brinogen, but 
not CRP levels were higher in diabetics with hypoechogenic 
plaques, identiﬁ ed by ultrasound, as compared with diabetics with 
hyperechogenic plaques (4.6 mg/l vs 3.6 mg/l, p = 0.007).
Markers of plaque remodeling
Diabetic patients with histologically identiﬁ ed ulcerated 
carotid plaques had signiﬁ cantly higher plasma levels 
Figure 1 (A) TF activity in plasma samples taken prior to endartrectomy in diabetics and symptomatic patients measured was higher in patients presenting hypoecho-
genic plaque on ultrasound as compared with patients with hyperechogenic plaque (p = 0.03). (B) On regression plot in the same group of patients there was correlation 
between TF activity in plasma and intramural levels of MMP-8 (p = 0.03, r2 = 0.2). 
Abbreviations: MMP, metalloproteinases; TF, tissue factor. 
Figure 2 (A) Regression plot for symptomatic, diabetic patients with hypoechogenic plaque on ultrasound with correlation between intramural TF levels and circulating 
active MMP-8 (p = 0.02, r2 = 0.6) (B) Regression plot for symptomatic, diabetic patients with hypoechogenic plaque on ultrasound with correlation between intramural TF 
levels and intramural D-dimer levels (p = 0.001, r2 = 0.4).
Abbreviations: MMP, metalloproteinases; TF, tissue factor.
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of MMP-8 than diabetics with stable, ﬁ brous plaques 
(p = 0.01, Figure 4a). In symptomatic, diabetic patients 
with hypoechogenic plaques, identiﬁ ed by ultrasound, 
there was a correlation between total cholesterol levels and 
intramural MMP-8 levels (p = 0.02, r2 = 0.5, Figure 4b). 
On western blot diabetic patients had higher plaque TF, 
active MMP-8, but not MMP-9 expression. The later was 
more expressed in diabetics with ulcerated, hemorrhagic 
plaques. Representative western blots are presented in 
Figure 5.
Figure 3 (A) Diabetics with symptomatic carotid disease had higher levels of plasma D-dimer if the plaque was hypoechogenic on ultrasound as compared with patients 
with hyperechogenic plaque (p = 0.007). (B) Diabetics with ulcerated plaque had more plasma D-dimer than diabetics with fi brose plaque (p = 0.02). (C) Diabetics with 
symptomatic carotid disease had higher levels of plasma D-dimer as compared with diabetic asymptomatic patients (p = 0.03).
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Discussion
In this study, diabetic patients with unstable carotid 
disease measured by the presence of symptomatic carotid 
disease, plaque echogenecity on ultrasound, or plaque 
vulnerability as evidenced by ulceration on histology, 
had significantly higher levels of markers of hemostasis, 
fibrinolysis and plaque remodeling compared with 
diabetics with stable disease.
TF is thought to be responsible for the prothrom-
botic state in patients with diabetes, and development 
of significant carotid artery stenosis with associated 
plaque remodeling (Sambola et al 2003; Vaidyula et al 
2006). Mononuclear cells and monocytes from patients 
with type 2 diabetes have increased procoagulant activ-
ity as measured by TF expression (Konieczkowski and 
Skrinska 2001). Increased synthesis of TXA2 and TF 
may potentiate thrombosis and increase fibrin deposition, 
events that play primary roles in the development of vas-
cular disease. During hyperglycemia-hyperinsulinemia, 
which is a characteristic of type 2 diabetes, elevation of 
plasma coagulation factors may constitute a potential 
for enhanced thrombin generation and thrombosis when 
triggered by exposure of TF, such as during arterial 
plaque rupture (Corti et al 2004; Vaidyula et al 2006). 
Changes of the TF pathway of blood coagulation have 
been described in diabetes and could be involved in its 
vascular complications.
Samad and colleagues (2001) found that hyperinsulinemia 
associated with insulin-resistant states, such as obesity and 
noninsulin-dependent diabetes mellitus, induced local TF 
gene expression in multiple tissues, thus contributing via the 
TF pathway to the increased risk of atherothrombotic disease. 
There was a strong correlation between expression of the recep-
tor for advanced glycation end products (RAGE) and TF, in 
long-standing uncontrolled type 2 diabetics (Buchs et al 2004). 
In our study, diabetics with symptomatic carotid disease had 
increased circulating tissue factor. Numerous hemostatic fac-
tors like vWF, t-PA, PAI-1 are increased in patients with type 2 
diabetes or impaired glucose tolerance. Recently, TF was shown 
to be associated with existing microvascular and neurogenical 
complications in patients with type 2 diabetes, and also corre-
lated with tPA and vWF expression. Patients with diabetes and 
TF concentrations of >3,000 pg/ml were 15 times more likely 
to present with microvascular disease and 10 times more likely 
to have neurogenical complications (Sommeijer et al 2006). In 
elderly patients with IGT, intermediates of the TF pathway, ie, 
TFPI are already increased as compared with normal subjects. 
Interestingly, endothelium-dependent hemostatic markers do not 
appear to correlate with lipid metabolism (Leurs et al 2002) 
Cell-derived microparticles support coagulation and 
inflammation and they may be involved in accelerated 
atherosclerosis in diabetic patients (Morel et al 2006). TF, 
possibly of granulocytic origin, was exposed on microparticle 
subpopulations in asymptomatic patients with well-regulated 
Figure 5 Representative Western blot showing TF protein levels (47 kDa), pro- and active MMP-8 (85 and 64 kDa, respectively) and pro- and active MMP-9 (92 and 78 kDa, 
respectively) in CEA plaques from diabetic (Pt1*, Pt2*, Pt4*, and Pt6*) and nondiabetic (Pt3, Pt5, and Pt7) patients. Ponceau staining of the membranes (not shown) and 
beta-smooth muscle actin (β-SMA) were used as loading controls. C (−) is a negative control, blots were incubated without primary antibodies to TF, MMP-8, and MMP-9.
Abbreviations: CEA; MMP, metalloproteinases; TF, tissue factor.
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type 2 diabetes. TF-positive microparticles were asociated 
with components of the metabolic syndrome but not with 
coagulation. Thus, the presence of TF on microparticles 
may be involved in processes other than coagulation, 
including transcellular signaling or angiogenesis (Diamant 
et al 2002). 
In this study population no differences in markers of 
thrombosis or plaque stability were found between diabetics 
and nondiabetics. However, diabetic and symptomatic patients 
with hypoechogenic plaques, identiﬁ ed on ultrasound, had 
increased expression of circulating and intramural markers of 
thrombosis, ﬁ brinolysis, and plaque remodeling as compared 
with patients with stable disease. Other factors and not only 
diabetes itself may affect changes within the arterial wall and 
subsequent remodelling leading to symptomatic vascular disease. 
In noncomplicated patients, the increase in FVII and TFPI 
was highly dependent on obesity index and age rather than on 
diabetes itself (Vambergue et al 2001). In the study described 
here, diabetic patients with hypercholesterolemia had higher 
intramural MMP-8 levels. Tissue factor activity correlated 
with intramural MMP-8 levels in diabetics with vulnerable 
carotid disease, suggesting that plaque remodeling may induce 
prothrombotic activity. Furthermore, in this vulnerable group 
of patients there was a signiﬁ cant correlation between total 
cholesterol levels and intramural MMP-8 and the presence 
of intramural TF and circulating active MMP-8. Independent 
of plaque stability, in diabetic patients, there was correlation 
between intramural MMP-8 and circulating TF activity. MMP-8 
levels are of special interest since it is known to be released from 
neutrophils at sites of inﬂ ammation and vascular disease and can 
cleave TF pathway inhibitor, thereby decreasing its anticoagulant 
activity (Cunningham et al 2002; Krupinski et al 2007). Baugh 
and colleagues (2003) however, could not demonstrate abnormal 
differences in MMP-1, -3, -9 productions in blood moncytes 
in type 2 diabetic patients. MMP expression and activity 
therefore remains controversial (Turu et al 2006). Further it is 
well established that RAGE plays a central role in the process 
of plaque destabilization in the diabetic patients. It has been 
demonstrated that enhanced expression of COX-2/mPGES-1 in 
human symptomatic plaques is associated with MMP-induced 
plaque rupture (Cipollone et al 2001, 2003). We found the 
correlation between the circulating TF and intramural MMP-8 
expression. This may have further patophysiological implications 
in a view of recent ﬁ ndings suggesting that statins may inhibit 
plaque RAGE expression by inhibiting the biosynthesis of PGE2-
dependent MMPs (Cuccurullo et al 2006). Further studies should 
address to answer if by control of plaque stability we also reduce 
prothrombotic state in diabetic patients.
Prothrombotic markers were independent from markers 
of inﬂ ammation like CRP, ﬁ brinogen or leucocyte count. Our 
results, demonstrate a link between the processes of plaque 
remodelling and increased risk of thrombosis. Our study sug-
gests, that diabetics may be a choice group for identiﬁ cation 
of key molecules participating in atherosclerosis and related 
risks of vascular complications. Identiﬁ cation of circulating 
risk molecules may directly reﬂ ect local advances in athero-
sclerosis and may help to identify diabetic patients with high 
risk of vascular complications.
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